Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Efficacy And Safety Study Intravenous Edotecarin In Patients With Advanced Gastric Cancer That Has Progressed Or Recurred After Prior Fluropyrimidine-Based Chemotherapy

NCT00087503 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00087503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00087503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Efficacy And Safety Study Intravenous Edotecarin In Patients With Advanced Gastric Cancer That Has Progressed Or Recurred After Prior Fluropyrimidine-Based Chemotherapy
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2004
Completion date
June 30, 2005
Enrollment
28
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

stomach neoplasms